Leaders of Shaanxi Provincial Food and Drug Administration visited Xi'an Libang Pharmaceutical Co., Ltd. for research and guidance

On the morning of February 27, Zhang Xiaoning, Secretary of the Party Leadership Group and Director of the Shaanxi Provincial Food and Drug Administration, led a group of 5 people in Lu Qiang, Director of the Xi'an Food and Drug Administration, Li Dayue, Deputy Inspector, Shen Siqing, Director of the Pharmaceutical Production Supervision Department, Yanta District Accompanied by Zhang Huajun, director of the Food and Drug Administration, he visited Xi'an Libang Pharmaceutical Co., Ltd. located on the Science and Technology Road of Xi'an High-tech Zone to carry out research activities. Libang Medical Industry Group President Ju Jianbo, Vice President Hui Minquan, Libang Pharmaceutical Factory Director Hu Huali and other leaders accompanied them.

During the symposium, Mr. Ju extended a warm welcome to all the leaders for their visit, and expressed his sincere thanks to the governments at all levels for their support, care and help to Libang over the years! The company profile, main business, product introduction, economic operation, quality management, future outlook and other aspects are introduced in detail.

The research team listened to the report and learned more about the difficulties and problems encountered in the company's current development process. Director Zhang expressed his support for Libang to build an FDA export base in Northwest China and made it clear that the provincial and municipal bureaus will give active help; at the same time, he emphasized that experts will be organized to study in time for the difficulties, problems and related suggestions of enterprises, and the provincial and municipal bureaus will help enterprises to coordinate as soon as possible solve.

Subsequently, Director Zhang and his party visited the production workshop, inquired about the production management and quality management in detail, and gave affirmation. Hu Huali introduced the layout, quality management, production process, etc., and focused on the company's investment in the production automation of Limengxin Injection and Libangxitong Injection in recent years and the achievements in improving production efficiency.

The company will take this survey as an opportunity to continue to make three good drugs with "good curative effect, good quality and good service", continuously improve the GMP management level, strictly control the quality, create more high-quality products, and devote itself to continuously improving product technology and innovation ability, gradually realize the beautiful goals of the enterprise, and make new contributions to the cause of human health.